ME-609
Phase 2Small molecule
ME-609 is one of 10 small molecule programs targeting Herpes Labialis. It is currently in Phase 2.
1
Indications
4
Total Trials
0
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
20 competitors in Herpes Labialis
#DrugCompanyPhaseTrials
1Famvir
NovartisApproved
Valtrex
GGlaxo Dba Glaxosmithkline
Approved
Zovirax
BBp Consulting, Inc
Approved
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Glutamine
SanofiPhase 2
NB-001
NNobias Therapeutics, Inc.
Phase 3
Abreva
HHALEON
Phase 2
Squaric Acid Dibutyl Ester
SSquarex, LLC
Phase 2
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Preclinical
ME-609
MMedivir
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Herpes Labialis1 trial
Immunocompromised1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ME-609. EMBL-EBI & Wellcome Sanger Institute.
- [4]